NCT01524289

Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 306 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the efficacy and tolerability of adding anacetrapib to ongoing statin therapy in participants with heterozygous familial hypercholesterolemia (HeFH).

Conditions

• Hyperlipoproteinemia Type II
• Hypercholesterolemia, Familial

Interventions

Type	Name	Description
DRUG	Anacetrapib	One oral tablet, orally once daily for 52 weeks
DRUG	Placebo	One oral tablet once daily for 52 weeks

Timeline

• Start date: 2012-02-03
• Primary completion: 2014-02-12
• Completion: 2018-11-13
• First posted: 2012-02-01
• Last updated: 2019-10-14
• Results posted: 2019-08-28